Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1 4Phase 4 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Specimen Handling 5Enoxaparin 5Carboplatin 5Bevacizumab 5Nivolumab 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Lutetium × Clear all
NCT05803941 2026-06-04

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis

Phase 4 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡